Q3 EPS Forecast for Denali Therapeutics Increased by Analyst

Denali Therapeutics Inc. (NASDAQ:DNLI) – Stock analysts at William Blair boosted their Q3 2025 earnings estimates for Denali Therapeutics in a research report issued to clients and investors on Tuesday, August 12th. William Blair analyst M. Minter now forecasts that the company will post earnings of ($0.77) per share for the quarter, up from their previous estimate of ($0.84). William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. William Blair also issued estimates for Denali Therapeutics’ Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.09) EPS, FY2026 earnings at ($3.49) EPS, FY2027 earnings at ($2.78) EPS and FY2028 earnings at ($0.41) EPS.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Monday, August 11th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.02. During the same quarter in the previous year, the firm earned ($0.59) earnings per share.

A number of other analysts have also recently commented on the stock. Wedbush reduced their target price on shares of Denali Therapeutics from $32.00 to $30.00 and set an “outperform” rating for the company in a report on Wednesday, May 7th. HC Wainwright dropped their price target on shares of Denali Therapeutics from $80.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Bank of America dropped their target price on shares of Denali Therapeutics from $28.00 to $27.00 and set a “buy” rating for the company in a research report on Monday, May 19th. TD Cowen upgraded shares of Denali Therapeutics to a “strong-buy” rating in a research report on Monday, July 28th. Finally, Robert W. Baird lowered their price objective on shares of Denali Therapeutics from $30.00 to $29.00 and set an “outperform” rating for the company in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $33.85.

Denali Therapeutics Stock Up 1.7%

DNLI opened at $14.70 on Thursday. The company has a quick ratio of 9.56, a current ratio of 10.27 and a debt-to-equity ratio of 0.01. The firm has a 50 day moving average price of $14.30 and a 200-day moving average price of $15.36. Denali Therapeutics has a twelve month low of $10.57 and a twelve month high of $33.33. The stock has a market capitalization of $2.15 billion, a price-to-earnings ratio of -5.25 and a beta of 1.36.

Insider Transactions at Denali Therapeutics

In other news, CEO Ryan J. Watts sold 495,282 shares of the firm’s stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $15.00, for a total value of $7,429,230.00. Following the completion of the sale, the chief executive officer owned 253,071 shares in the company, valued at approximately $3,796,065. This trade represents a 66.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Alexander O. Schuth sold 2,937 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the sale, the insider owned 242,346 shares of the company’s stock, valued at $3,291,058.68. This trade represents a 1.20% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 501,962 shares of company stock worth $7,520,799. 12.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Denali Therapeutics

Institutional investors have recently made changes to their positions in the company. Envestnet Asset Management Inc. lifted its holdings in Denali Therapeutics by 34.5% during the 4th quarter. Envestnet Asset Management Inc. now owns 37,622 shares of the company’s stock valued at $767,000 after buying an additional 9,643 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Denali Therapeutics during the 4th quarter valued at about $533,000. Sterling Capital Management LLC lifted its holdings in Denali Therapeutics by 589.9% during the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company’s stock valued at $36,000 after buying an additional 1,516 shares in the last quarter. Barclays PLC lifted its holdings in Denali Therapeutics by 8.7% during the 4th quarter. Barclays PLC now owns 278,067 shares of the company’s stock valued at $5,666,000 after buying an additional 22,184 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Denali Therapeutics during the 4th quarter valued at about $328,000. Institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.